HeartSciences Inc. (HSCS)

Market Cap	13.69M +55.1%
Revenue (ttm)	4,319 -0.7%
Net Income	-9.14M
EPS	-3.48
Shares Out	3.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	227,901
Open	3.860
Previous Close	4.120
Day's Range	3.380 - 4.015
52-Week Range	1.630 - 4.350
Beta	1.86
Analysts	Buy
Price Target	10.00 (+184.9%)
Earnings Date	Sep 22, 2026

About HSCS

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic EC...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 15, 2022
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: HSCS
• Website: https://heartsciences.com

Financial Performance

In fiscal year 2026, HeartSciences's revenue was $4,319, a decrease of -0.71% compared to the previous year's $4,350. Losses were -$9.14 million, 4.30% more than in 2025.

Analyst Summary

According to 2 analysts, the average rating for HSCS stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 184.90% from the latest price.

Price Target

$10.0

(184.90% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 11, 2026

Data Sources Report a data error